僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用. Enavatuzumab （PDL192; ABT-361） is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis （TWEAK）. TWEAK （Fn14; TNFRSF12A）, the natural ligand of the TWEAK receptor （TweakR）, stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity （ADCC）. Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo